


# CUPISCO - Study Design

International phase II, randomized, active-controlled, multicenter study comparing efficacy and safety of targeted or immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with newly diagnosed poor-risk CUP



## Status

- 34** Countries
- 188** Centers
- 790** Patients with newly diagnosed CUP
- 7/18** First patient in




# CheCUP - Single Arm, Multicenter, Phase II Trial in Platinum-refractory CUP-Syndrome

## Nivolumab + Ipilimumab in platinum-refractory carcinoma of unknown primary

- Immune checkpoint inhibitor treatment with nivolumab + ipilimumab prolongs survival in patients with platinum-resistant CUP syndrome
- Tumor mutational burden predicts response to nivolumab + ipilimumab in patients with platinum-resistant CUP syndrome

### Status

10 Centers  
194 Patients  
12/19 First patient in



Primary endpoint: Progression-free survival